Abstract:Young women with breast cancer are at higher risk of locoregional recurrence in comparison with elder women. The study aimed to determine the factors related to locoregional recurrence and the impact of post-mastectomy radiotherapy in women ≤35 years old. Between February 1989 and December 2004, 459 patients ≤35 years old with operable breast cancer who treated mastectomy were retrospectively analyzed. The type of surgery included: radical mastectomy (47.4%), extended radical mastectomy (11.5%) and modified radical mastectomy (MRM; 39.6%). The percentage for T1, T2, and T3 tumor was 22.0%, 52.3%, and 10.0%, respectively. Lymph node without metastasis accounted for 25.7% of all and N1, N2, and N3 lymph node accounted for 25.5%, 20.7%, and 14.6%. Four hundred twenty-three patients received chemotherapy and 160 patients received endocrine therapy. PMRT was administered in 220 patients (47.9%). Radiation field included supraclavicular lymph node and internal mammary nodes only in 187 and 170 patients while chest wall was treated in 25 patients. Median age of this cohort was 32 years old and median follow-up was 50.1 months. The median disease-free interval to first isolated locoregional recurrence was 17.8 ± 2.7 months. The 5-year and 10-year isolated locoregional control rate (ILRCR) was 74.9% and 70.0%, respectively. The most common site of recurrence was CW (106/131) followed by SN (18/131). The 5-year CW control rate decreased with more advanced T and N Stage (p<0.05). Compared to the patients with no ILR, patients with ILR had a shorter 5-year metastasis-free survival (MFS) (66.6% vs. 53.8%; p = 0.003). In univariate analysis, surgical modality, tumor size, lymph node status, chemotherapy and ILR were significant predictors for overall survival (OS). In multivariate analysis, only higher T-Stage (p = 0.041; HR = 1.69; 95% CI = 1.02 – 2.16) was the independent predictor for isolated chest-wall recurrence (ICWR) while higher N-Stage (p = 0.005; HR = 1.58; 95% CI = 1.15 – 2.78) was the additional predictor for ILR besides higher T-Stage (p = 0.047; HR = 1.58; 95% CI = 1.02 – 2.42). Higher T-Stage (p = 0.014; HR = 1.52; 95% CI = 1.09 – 2.12), higher N-Stage (p < 0.001; HR = 2.25; 95% CI = 1.67 – 3.03), the use of endocrine therapy (p = 0.014; HR = 0.59; 95% CI = 0.39 – 0.90) and ICWR (p = 0.006; HR = 1.87; 95% CI = 1.20 – 2.91) are independent predictors for MFS. As to OS, all factors above were independent prognostic factors for OS except for the endocrine therapy administration (p > 0.05). Young women with operable breast cancer receiving mastectomy have a high risk of ILR and shorter disease-free interval. It is critical to re-evaluate the impact of PMRT in young patients. Chest-wall remains the region with higher risk of recurrence and should not be neglected as PMRT target.

Can a Subgroup at High Risk for LRR Be Identified from T1-2 Breast Cancer with Negative Lymph Nodes after Mastectomy? A Meta-Analysis

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

High Risk For Non-Sentinel Node Metastasis In Breast Cancer Patients With Sentinel Node Metastases

Analysis In Early Stage Triple-Negative Breast Cancer Treated With Mastectomy Without Adjuvant Radiotherapy: Patterns Of Failure And Prognostic Factors

Impact of Clinical-pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Can We Omit Adjuvant Radiotherapy?

67P Analysis of Local-Regional Recurrence in Young Women (≤ 35Y) Receiving Mastectomy for Operable Breast Cancer

Risk Stratification Model for Prediction of Locoregional Recurrence in Patients with Pathologic T1-2N0 Breast Cancer after Mastectomy

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?

Locoregional Recurrence Analysis in Young Women (≤35 Years) Receiving Mastectomy with Operable Breast Cancer

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction

Risk Factors of Locoregional Relapse in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy Following Mastectomy and Radiotherapy

Potential Prognostic Value of the Lymph Node Ratio and Its Correlation with Circulating Sex Hormone Concentration in Pathological T1/2 Breast Cancer Patients: a Retrospective Study

The prognostic values of lymph node ratio for gynecological cancer: a systematic review and meta-analysis

Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis

Nodal Ratio of Positive to Excised Nodes, but Not Number of Positive Lymph Nodes is Better to Predict Group to Avoid Chemotherapy among Postmenopausal ER-positive, Lymph Node-Positive T1-T2 Breast Cancer Patients.

Predicting Locoregional Recurrence in Triple-Negative Breast Cancer Using Novel Molecular Subtyping.

Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?

ER, PR and Her-2 in the prediction of locoregional recurrence in node positive breast cancer treated with mastectomy